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Abstract
Objectives: There is a need for better, noninvasive quantitative biomarkers for assessing the rate of progression and
possible response to therapy in spinal muscular atrophy (SMA). In this study, we compared three electrophysiological
measures: compound muscle action potential (CMAP) amplitude, motor unit number estimate (MUNE), and electrical
impedance myography (EIM) 50 kHz phase values in a mild mouse model of spinal muscular atrophy, the Smn1
c/c mouse.
Methods: Smn1
c/c mice (N=11) and wild type (WT) animals (2/2, N=13) were measured on average triweekly until
approximately 1 year of age. Measurements included CMAP, EIM, and MUNE of the gastrocnemius muscle as well as weight
and front paw grip strength. At the time of sacrifice at one year, additional analyses were performed on the animals
including serum survival motor neuron (SMN) protein levels and muscle fiber size.
Results: Both EIM 50 kHz phase and CMAP showed strong differences between WT and SMA animals (repeated measures 2-
way ANOVA, P,0.0001 for both) whereas MUNE did not. Both body weight and EIM showed differences in the trajectory
over time (p,0.001 and p=0.005, respectively). At the time of sacrifice at one year, EIM values correlated to motor neuron
counts in the spinal cord and SMN levels across both groups of animals (r=0.41, p=0.047 and r=0.57, p =0.003,
respectively), while CMAP did not. Motor neuron number in Smn1
c/c mice was not significantly reduced compared to WT
animals.
Conclusions: EIM appears sensitive to muscle status in this mild animal model of SMA. The lack of a reduction in MUNE or
motor neuron number but reduced EIM and CMAP values support that much of the pathology in these animals is distal to
the cell body, likely at the neuromuscular junction or the muscle itself.
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Introduction
A variety of mouse models of spinal muscular atrophy (SMA)
have been developed over the past decade [1]. These include
animals with relatively severe phenotypes, such as the survival
motor neuron negative (Smn
2/2), Smn2
+/+, and SMND7 models
[2–4], all of which die within the first 3 weeks of life, to relatively
long lived models, including the Smn1
c/c mouse, which develops
only subtle motor deficits [5]. The impetus underlying the
development of these various models is based on an effort to
recapitulate the marked varying human disease severities, with the
SMND7 model mimicking Type 1 SMA and Smn1
c/c mimicking
SMA Type 3. While each of these disease models has its unique
features, nearly all of the longer-lived models develop some
element of digital, ear, and tail necrosis [5].
A major purpose of these models is to evaluate potential
therapies. Beyond measuring survival, which is effective in the
study of more severe models [6,7], biomarkers are needed to
evaluate more subtle therapeutic effects, such as disease stabiliza-
tion or slowing of progression. A variety of such biomarkers have
been explored in both animals and humans, including serological
biomarkers measures such as SMN expression [8], functional
measures [9], muscle imaging [10,11], as well as electrophysiologic
markers, including motor unit number estimate (MUNE) and
compound motor action potential amplitude (CMAP) [12–14].
More recently, the technique of electrical impedance myography
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bioimpedance-based procedure in which a high-frequency electri-
cal current is applied to a localized area of muscle and the
consequent voltages measured [15]. The voltages reflect changes
in both muscle membrane health and size and well as local
compositional changes to the muscle. A longitudinal study in
children with mainly older SMA Type 2 and Type 3 patients has
shown the relative stability of EIM values over time, in contrast to
normal children who show increasing EIM phase values with age,
consistent with progressive muscle growth and maturation [16].
Since EIM is non-invasive, painless, and simple to apply, it may be
especially useful in young children and is currently being
investigated as a part of a multicenter study.
In an effort to further refine and study EIM as a potential
technology that can be readily applied for assessment of SMA
therapies in both animals and humans, we undertook a study of
the Smn1
c/c mouse with two main goals. First, we were interested
in identifying differences in EIM, CMAP, and MUNE in a group
of Smn1
c/c mice longitudinally over an extended period of time
(up to 1 year of age). Second, we sought to determine how these
measures correlated to serologic biomarkers, including SMN levels
and histological data.
Methods
Animals
All procedures were approved by the Beth Israel Deaconess
Medical Center Institutional Animal Care and Use Committee
(IACUC). Breeding colonies of Smn1
c/c mice (strain: B6.129-
Smn1
tm5(Smn1/SMN2)Mrph/J) were established from animals ob-
tained from Jackson Labs (Bangor, Maine). Animals were
genotyped by tail snip.
Given that this animal model develops necrosis of the tail, pinna
of ear, and digits of hind-paw up to an age of approximately P90,
special care was mandated by our animal research facility.
Specifically, animals were not weaned until P28. Special bedding
and gel-packs (DietGel 76A, PharmaSer, Framingham, MA) were
provided at all times. As long as necrosis was present, the animal
was provided meloxicam subcutaneously daily. Any animal
developing paw (as compared to digital necrosis) or losing more
than 20% body weight was euthanized. No electrophysiological or
behavioral measurements were allowed until the necrosis had
completely resolved, which was at approximately 15 weeks of age.
A total of only 7 Smn1
c/c and 7 wild-type (WT) mice were
ultimately studied for the full 15–52 week duration post necrosis
and included in the longitudinal analysis. An additional 4 Smn1
c/c
and corresponding 6 WT animals were ultimately also included
and followed out to 52 weeks, at which time all animals were
measured a final time and sacrificed.
Experimental design
There were two separate components to the study, the first
being a longitudinal element, in which animals were followed at a
regular intervals from 15 weeks of age until 1 year of age, and the
second being a cross-sectional element, when the animals were all
sacrificed at approximately 1 year of age. Body weight, front paw
grip strength, CMAP, MUNE, and EIM were obtained on a
regular basis for 37 weeks. At approximately 1 year of age all
animals were sacrificed, at which time gastrocnemius muscle,
spinal cord (L4–5), and whole blood were collected for further
analysis.
Functional study
The front paw grip strength was measured by a grip strength
meter single computerized sensor with standard pull bars (CAT #
1027CSM, Columbus Instruments). The animal was allowed to
grasp a small bar connected to a sensitive force transducer.
Holding the lower back of the animal, the investigator (JL) pulled
the animal away from the bar until it lost its grip. The maximum
force recorded out of 5 trials was recorded.
Figure 1. Trajectories of change (6 standard deviation) over the period of 15 weeks to 52 weeks for the 7 Smn1
c/c animals (in black)
and 7 WT animals (in gray) followed for the entire duration. Data is normalized to baseline with a least squares fit of the data. Only weight
and EIM showed significant differences in the trajectories between the groups.
doi:10.1371/journal.pone.0111428.g001
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CMAP and MUNE were performed on the left hind limb via
TECA Synergy T2 EMG Monitor System (Viasys, Madison, WI)
while the animal was under anesthesia, as previously described
[17]. Briefly, the sciatic nerve was supramaximally stimulated at
the sciatic notch and the entire distal leg muscle compartment
recorded via disposable ring electrodes with a ground electrode
placed on the right hind paw to record the CMAP [18,19]. For
MUNE, we followed a previously published incremental approach
for use in animals described by others [20,21]. Briefly, 10
incremental steps were recorded and averaged to determine the
average single motor unit potential amplitude. The MUNE was
calculated by dividing the CMAP amplitude by the average single
motor unit potential amplitude. Of note, the MUNE analysis
would have been more complete had multiple methods been used
to confirm the MUNE, including multipoint [22] and modified
multipoint [23]. However, these were not attempted given the
already complex data set being collected; in addition, performing
these methods in a mouse are extremely difficult given their small
size and the need to move stimulating electrodes to different point
along the nerve.
EIM study
All EIM measurements were performed with the animals placed
under 1% isoflurane anesthesia delivered through a nose cone with
a heating pad underneath the limb to maintain consistent
temperature. The leg was then taped to the measuring surface at
an approximately 45u angle extending out from the body, away
from the head.
A fixed 4-electrode array was placed over the gastrocnemius
muscle, as previously described [17]. EIM measurements were
performed with a Skulpt Inc EIM1103 system (San Francisco,
CA).
Serological, pathological and histological studies
1. SMN protein concentration. The whole blood was obtained
via cardio-puncture and preserved at 280uC. These samples were
analyzed by PharmOptima with an electrochemiluminescence-
based SMN immunoassay developed by PharmOptima (Portage,
MI), using Meso Scale Discovery technology. 2. Muscle weight
and myocyte fiber area. The entire gastrocnemius muscle was
immediately excised at its proximal end just below the knee and
cutting the gastrocnemius tendon distally, and its mass obtained.
Figure 2. Column plots comparing 1-year end point data for WT and SMA animals. While most of the readily obtained measures, including
body weight, paw grip strength, and muscle size are smaller and SMN is markedly reduced, all electrophysiological parameters show only modest
differences. In addition, hydroxyproline, a measure of muscle fibrosis, is non-significantly increased in the SMA animals. *,0.05, **,0.01, ***,0.001.
doi:10.1371/journal.pone.0111428.g002
Figure 3. Test-retest reproducibility of EIM recorded from the
mouse gastrocnemius at the one year end point.
doi:10.1371/journal.pone.0111428.g003
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nitrogen and stored at 280uC. The tissue was then cut into 5 mm
slices and stained with hematoxylin and eosin. Stereological
measurements were made using a Zeiss Axiophot microscope with
a motorized stage interfaced with a Dell Optiflex 380 computer
running Stereo Investigator (MBF Biosciences, Inc., Williston, VT)
software. Approximately 30 cells from each muscle were evaluated
in a blinded fashion by a single investigator (TG). 3. Hydroxy-
proline level. In order to assess the quantity of connective tissue in
the muscle as a consequence of disuse/neuronal loss, a commer-
cially available assay (Kit #6017, Chondrex, Inc. Redmond, WA)
was used to measure muscle hydroxyproline content. 4. Spinal
cord motor neuron number. All animals were perfused and then
fixed with 4% Formalin. To keep the spinal cord intact, the whole
spinal column was removed and then decalcified by EDTA over
several days. Then, the lumbar 4 and 5 levels of the spinal cord
were removed, cut into 5 mm section in paraffin, and stained by
cresyl violet. Bilateral motor neuron number in the anterior horn
on each section was counted blind to group designation. Regions
of interest were counted at 40X magnification using a Zeiss
Axiophot microscope interfaced with a Dell Optiflex 380
computer running Stereo Investigator (MF Biosciences, Inc,
VT). The region of interest was sub-divided into sections using
the optical fractionator within the Stereo Investigator software and
examined individually. Inclusion of a cell as a motor neuron was
based on cell size, centering of nucleus within the cell, and the
amount of cytoplasm within the cell.
Data analysis
In order to utilize all the data obtained, differences between
animals were initially assessed via repeated measures 2-way
ANOVA, in which the independent variable was group and
dependent variable the individual electrophysiological measures.
However, in order to mirror standard practices in clinical trials,
trajectories of change were then calculated for each individual
animal over time (fit via linear regression anchored to the baseline
visit), comparing the slopes of the trajectories for each of the
measures between groups of animals. Unpaired t-tests and Pearson
correlation analyses were also performed to determine the
relationship between various functional, electrophysiological,
pathological, and histological studies at the time of sacrifice at
one year of age. For all statistical tests, significance was determined
at p,0.05, two-tailed. All results are summarized as mean 6
standard error.
Results
Differences between groups for the three main
physiological measures: CMAP, MUNE, and EIM
In order to effectively capture all the data from multiple visits in
the comparison between groups, we performed a two-way
repeated measures ANOVA. There was a highly significant group
effect for EIM (F(12,130) =44, p,0.001) and a similarly strongly
significant group effect for CMAP (F (12,130)=26, p,0.001) but a
non-significant group effect for MUNE (F (12,130)=0.31,
p=0.58,). A significant interaction term (p,0.001) was also
present for EIM but not MUNE or CMAP.
Longitudinal trajectories for all measures
As Figure 1 demonstrates, of the three electrophysiological
parameters, only EIM demonstrated a significant difference over
time in the SMA mice as compared to the WT mice, although the
difference appeared to be due mainly to increasing values for the
WT animals rather than to a reduction in values in the SMA
animals. Animal weight showed a similar trajectory.
End point-cross sectional study
Figure 2 provides a summary of the endpoint data for the two
groups of animals. Figure 2a, 2b, and 2c show that body weight,
front paw grip strength, and gastrocnemius muscle mass in the
SMA animals were reduced compared to controls (p,0.01 for all);
of note, muscle mass was 32.8% lower in the SMA animals as
compared to WT. Figure 2d, 2e and 2f show that there were
borderline significant differences between the groups for both EIM
(p=0.045) and CMAP (p=0.043); MUNE showed no significant
difference between the groups.
Figure 2g, 2h, 2i and 2j showed the significant differences
between the groups for both SMN concentration (p,0.001) and
myocyte area (p=0.043); Spinal cord motor neuron count and
hydroxyproline level did not show a significant difference between
the groups.
Figure 3 shows test-retest repeatability of the endpoint data; as
can be seen, the repeatability is good with an intra-class
correlation coefficient of greater than 0.90.
End Point Correlations
The correlations are summarized in Table 1, with selected
correlations provided in Figure 4. Among electrophysiological
measures, only EIM showed the most consistent correlations with
serological, pathological and histological measures, as presented in
Figure 4a (SMN concentration, r=0.57, p=0.003), 4b (hydroxy-
proline level, r = 20.50, p=0.019), and 4c (spinal cord motor
neuron count, r=0.41, p=0.047), although it did not correlate
significantly with muscle fiber size. Interestingly, EIM phase also
correlated to CMAP (Figure 4d, r=0.44, p=0.04) whereas it had
a poor correlation with MUNE (Figure 4e, r = 20.33, p=0.12).
Discussion
Overall, the results of this study support that EIM is sensitive to
disease status in Smn1
c/c mice. Of the 3 electrophysiological
biomarkers, both EIM and CMAP revealed significant differences
between WT and SMA animals and only EIM revealed a
difference in trajectory between the groups over the approximately
36-week period of study. This finding is analogous to the data
obtained in our longitudinal study of older children with SMA
[16]. While this EIM finding may appear useful, it is important to
also point out that body weight showed a very similar trend
(compare Figures 1a and 1c), which itself has been suggested as a
useful measure in the SMND7 mouse [24]. An obvious concern is
that EIM is proving nothing more than a surrogate for body
weight. In fact, it is not unreasonable to suspect that the two
measures are associated. A major component of body weight is
muscle mass, and EIM, while not a direct measure of muscle mass,
is deeply impacted by the number and size of muscle fibers [25].
Since more, larger fibers imply greater muscle mass and hence
greater body weight, it is not surprising that EIM and body weight
show similar trends. Another point worth highlighting is that while
the final measurements show a significantly lower CMAP for SMA
animals than for WT (Figure 2), the WT CMAP actually
decreased slightly over time whereas the SMA increased slightly
(Figure 1). This apparent paradox is explained by the fact that the
CMAP data in the SMA animals was lower throughout the study,
and although both groups’ values converged slightly over time,
they never approached the point of equivalence.
Interestingly, there were no significant differences between the
number of motor neurons in the spinal cords of the diseased mice
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normal number of neurons in the L3 and L4 ventral roots [5].
This is in contrast to features of reduced MUNE and normalized
CMAP because of collateral reinnervation that have been reported
in patients with mild SMA [12]. This discordance between the
animal model and the human disease is problematical and brings
into question the value of this model. Still we do know that SMN is
expressed in muscle as well [26], so it is possible that we are
identifying muscle specific effects that may still be relevant to
disease pathogenesis even if not primary motor neuron pathology.
What remains surprising, however, is that despite this, EIM
correlated to the motor neuron counts, perhaps suggesting some
general relationship between EIM values and the number of motor
neurons in a limb. It is also intriguing that EIM correlated to the
SMN protein concentration, a second somewhat unexpected
finding. Since SMN protein is expressed in muscle [26], it is
possible that SMN levels are correlating closely with muscle size
and weight, both of which are being captured in the EIM 50 kHz
phase data.
How can these seemingly disparate results be integrated? Since
there is no apparent loss of motor neurons, either by MUNE or
motor neuron counting in the spinal cord, the mildly reduced
CMAP and EIM values in the SMA as compared to WT suggest
pathology at the distal motor neuron or in the muscle itself. The
substantially greater loss of muscle weight as compared to
reduction in fiber size (34% vs. 18%) suggests that actual loss of
individual muscle fibers (e.g., due to denervation) rather than just
limited atrophy may be playing an important role in these findings.
Loss of motor neuromuscular junctional input, with subsequent
severe fiber atrophy, would be consistent with evidence that SMN
plays an important role in the distal nerve and skeletal muscle
[27,28]. Indeed, other work has shown that neuromuscular
junctions are abnormal in this model [5]. Primary muscle
abnormalities would have the effect of leaving MUNE unaltered
while at the same time reducing the EIM and CMAP values [29],
Further supporting this interpretation is the increase in hydroxy-
proline in the SMA animal muscle, suggesting increased connec-
tive tissue in the muscle, consistent with myopathic features that
have been described in SMA [30].
A major limitation of this study is that of 220 SMA animals
bred, only 11 ultimately could be studied due limitations placed on
us by our institution’s animal ethics committee. Inasmuch as the
degree of necrosis parallels the degree of motor neuron loss, we
may have evaluated only the most mildly affected animals.
Second, the small number of animals studied, the large number of
analyses performed, and the relatively modest p values for a
number of the outcomes implies that the study is subject to both
type 1 and type 2 error. Third, we only evaluated gastrocnemius, a
mildly affected muscle in this model [31]. However, we have been
developing approaches for measuring other muscles in the mouse
including tibialis anterior, quadriceps, fore limb and even axial
muscles using minute needle electrode arrays. Thus, this work can
be viewed as only an initial effort toward assessing muscle
condition in SMA mice using EIM. Fourth, we have only focused
on a single frequency of electrical current in these studies; it is
possible that multifrequency metrics could provide additional
valuable data.
In summary, these data support that EIM may a play a useful
role in the evaluation of mild SMA animals and that EIM data
correlate to some extent with other biomarkers. It also supports its
potential application in the study of human SMA. However, it is
clear that additional study of this and other models of SMA will be
needed to fully understand the complex relationship between
electrophysiological biomarkers and disease status.
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